Ten years after the original discovery of this potent molecule, VEGF still holds great therapeutic promise. But who said that it would be easy? Lee, R.J. et al. VEGF gene delivery to myocardium ...

Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...

The purpose of this article is not to review the literature that has been published on the molecular or biological properties of VEGF. For this, readers can consult other review articles on this ...

The drugs block VEGF, or vascular endothelial growth factor, a molecule that tells our bodies to make new blood vessels. This is where RNA editing comes in. In the lab, scientists have proven that ...

DARPin MP0112, an anti-VEGF molecule purported to have a 3-month therapeutic effect, has completed Phase II trials but a Phase III trial has not yet been announced. To decrease the number of ...

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...

Expert Rev Anticancer Ther. 2009;9(6):839-849. BAY43-9006 (Sorafenib) Small-molecule inhibitor BRAF, EGFR, c-kit, PDGFR, VEGFR-2 and 3 Phase II-III (in combination with chemotherapy) TKI258 (CHIR ...

4D Molecular (FDMT) Therapeutics announced the ... a recombinant protein that inhibits VEGF-A, VEGF-B and PlGF, and a microRNA sequence that inhibits expression of VEGF-C. The data showed that ...